fmc7 (fitc)* (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
fmc7 (fitc)*
Fmc7 (Fitc)*, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc7+(fitc)*/pm29659173-25-18-47
Average 90 stars, based on 1 article reviews
Fmc7 (Fitc)*, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fmc7+(fitc)*/pm29659173-25-18-47
Average 90 stars, based on 1 article reviews
fmc7 (fitc)* - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: A novel scoring system combining expression of CD23, CD20, and CD38 with platelet count predicts for the presence of the t(11;14) translocation of mantle cell lymphoma. Article Snippet: Then 50 lL of these cell suspensions were incubated with the following antibody combinations, concentrations varying according to each manufacturer’s recommendations: IgG1 FITC/IgG1 PE (BD/CD45 PerCP (BD), CD19 FITC/CD5 PE (Immunotech)/CD45PerCP (BD), Article Title: Usefulness of CD200 in the differential diagnosis of SDRPL, SMZL, and HCL. Article Snippet: The usefulness of CD200 in the differential diagnosis of chronic Bcell lymphoproliferative disease (CLPD) has been well illustrated in the recent article by Rahman et al1 published into international journal of laboratory hematology.. Although the evaluation of CD200 is not required in the diagnostic criteria for chronic lymphocytic leukemia (CLL) by the World Health Organization (WHO) 2016 classification as well as other CLPDs,2 its diagnostic value is now clearly established in multiple reports and its inclusion in the currently antibodies panel of CLPDs diagnosis is now advised.1,3,4 Indeed the CD200 expression appears pertinent in the differential diagnosis of CLPDs as mantle cell lymphoma (MCL) cases are usually CD200 negative in contrast to the other CLPD cases.. The splenic diffuse red pulp lymphoma (SDRPL) with villous lymphocytes is a rare indolent Bcell lymphoma designed in the WHO 2016 classification to the unclassifiable splenic Bcell lymphomas/ leukemias 2,5 mainly because of some overlapping features with the splenic marginal zone lymphoma (SMZL), hairy cell leukemia (HCL) and, especially its variant form (HCLv). Article Title: Selection of Epstein-Barr virus specific cytotoxic T lymphocytes can be performed with B lymphoblastoid cell lines created in serum-free media Article Snippet: The following mAbs were used for BLCL phenotyping: J4·119 (anti-CD19-APC), BL1a (anti-CD5-FITC), anti-CD79b-PE, 25·3.1 (anti-CD11a-PE), anti-CD40-PE, B6 (anti-CD23-FITC), anti-CD80-PE, anti-CD86-PE and j33 (anti-CD45-FITC) from Immunotech Products, HB7 (anti-CD38-PE), Leu-16 (anti-CD20-FITC), S-HCL-1 (anti-CD22-PE), 2A3 (anti-CD25-PE), W8E7 (anti-CD10-FITC), and anti-CD2-PE from BD Pharmingen, Le Pont de Claix, France, and |